AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Case of normal pregnancy after exposure to antidiabetic drugs reported.
2004 AUG 5 - (NewsRx.com & NewsRx.net) -- A case report from Turkey is the first in the literature to describe maternal and fetal outcome after exposure to the antidiabetic medications rosiglitazone, gliclazide and atorvastatin.
According to F. Yaris and colleagues, Karadeniz Tech University, "The subject is a diabetic and hypertensive woman treated early during an unplanned pregnancy with a multidrug regimen that included three drugs with no prior history for use in pregnant women (rosiglitazone, gliclazide, atorvastatin).
"She was under care for chronic hypertension, which she suffered for 14 years, and diabetes mellitus, hypercholesterolemia, anxiety disorder, morbid obesity and epilepsy for 5 years," they said.
Unaware she was pregnant, during the first 7 weeks of the pregnancy the woman was taking rosiglitazone (4 mg/day), gliclazide (60 mg/day) and atorvastatin (40 mg/day) in addition to acarbose, spironolactone, hydrochlorothiazide, carbamazepine, thioridazine, amitryptiline, chlordiazepoxide and pipenzolate bromide.
"Pharmacotherapy was adjusted following clinical recognition of pregnancy during the 8th week," Yaris and colleagues said. The woman ...
- FDA insists on cardiac warning for Avandia.(Antidiabetic drugs)(Food and Drug...
- Magazine article from: Chemistry and Industry Houlton, Sarah August 27, 2007 700+ words
Stronger warnings about possible cardiac side effects will have to be put on packs of all glitazone antidiabetic drugs in the US. The US FDA's (Food and Drug Administration) requirement for a boxed warning comes in the wake of the recent scare...
- Here's how to better manage oral antidiabetic drugs toxicity.(Report)
- Newspaper article from: Drug Formulary Review June 1, 2009 700+ words
Here's how to better manage oral antidiabetic drugs toxicity Poison expert offers guidance Most of the medication overdoses reported to the national Association of Poison Control...
- Levemir approved in Europe for use in combination with oral antidiabetic drugs.
- News wire article from: Chemical Business Newsbase March 1, 2007 700+ words
...Commission has approved Novo Nordisk's Levemir (insulin detemir) for once-daily use in combination with oral antidiabetic drugs. Levemir significantly improves blood glucose levels with less weight gain compared to NPH insulin and insulin...
- Endocrinologists and Primary Care Physicians Have Different Rationales Driving...
- Press release article from: PR Newswire November 29, 2004 700+ words
...that endocrinologists and primary care physicians have different rationales driving their choice of prescription antidiabetic drugs. Surveyed primary care physicians (PCPs) are more sensitive to cost and formulary status of antidiabetic agents...
- Next generation of antidiabetic drugs discussed: Tokyo seminar.
- News wire article from: Chemical Business Newsbase September 15, 2008 700+ words
An application for the extension of antidiabetic drug voglibose (brand name in Japan: Basen) to add impaired glucose tolerance (IGT) has been submitted for the first time in Japan, according to Professor Masato Odawara of the Third Department of Internal Medicine, Tokyo Medical University, during a
- Starlix approved for use in combination with popular thiazolidinedione class of...
- News wire article from: Asia Africa Intelligence Wire October 23, 2003 700+ words
(From Chemical Business NewsBase - Press Release) Novartis Pharmaceuticals Corp announced that the US Food and Drug Administration (FDA) approved Starlix (nateglinide) for use in combination with a thiazolidinedione (TZD) in patients with Type 2 diabetes who are not adequately controlled after a
- Starlix(R) Approved For Use in Combination with Popular Thiazolidinedione Class...
- Press release article from: PR Newswire October 23, 2003 700+ words
Novartis Pharmaceuticals Corporation announced today that the U.S. Food and Drug Administration (FDA) approved Starlix(R) (nateglinide) for use in combination with a thiazolidinedione (TZD) in patients with type 2 diabetes who are not adequately controlled after a therapeutic response to a TZD.
- Interim Study Results Presented at ADA 2009: Exenatide Not Associated With...
- Press release article from: PR Newswire June 7, 2009 700+ words
Retrospective Cohort Study Included More Than 25,000 BYETTA Patients Accrued Over Three Years NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced interim results from a retrospective study including nearly 260,000 patients that showed
- Interim Study Results Presented at ADA 2009: Exenatide Not Associated With...
- Newspaper article from: Diabetes Week June 22, 2009 700+ words
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) announced interim results from a retrospective study including nearly 260,000 patients that showed the risk of acute pancreatitis among patients initiating therapy with BYETTA(R) (exenatide) injection was not increased
- Type 2 diabetes puts older women at high risk of mental decline.
- Magazine article from: Women's Health Weekly March 18, 2004 700+ words
...with diabetes who were on oral antidiabetic drugs performed similarly to women...article was prepared by Women's Health Weekly editors from staff and other...Copyright 2004, Women's Health Weekly via NewsRx.com & NewsRx...
Source: HighBeam Research, Case of normal pregnancy after exposure to antidiabetic drugs...